United Therapeutics’ (UTHR) “Hold” Rating Reiterated at Cowen

Cowen reissued their hold rating on shares of United Therapeutics (NASDAQ:UTHR) in a research report released on Wednesday, May 1st, AnalystRatings.com reports. They currently have a $103.00 price objective on the biotechnology company’s stock.

UTHR has been the topic of several other reports. Credit Suisse Group restated an underperform rating and issued a $98.00 price objective (down from $105.00) on shares of United Therapeutics in a research report on Tuesday, March 26th. Wedbush set a $269.00 price objective on shares of United Therapeutics and gave the stock a buy rating in a research report on Monday, April 8th. BidaskClub cut shares of United Therapeutics from a hold rating to a sell rating in a research report on Friday, April 19th. ValuEngine cut shares of United Therapeutics from a hold rating to a sell rating in a research report on Thursday, April 18th. Finally, LADENBURG THALM/SH SH set a $124.00 price objective on shares of United Therapeutics and gave the stock a hold rating in a research report on Thursday, February 28th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average price target of $129.00.

Shares of UTHR opened at $90.65 on Wednesday. United Therapeutics has a twelve month low of $88.23 and a twelve month high of $130.00. The stock has a market cap of $3.91 billion, a PE ratio of 6.77 and a beta of 1.01. The company has a current ratio of 7.19, a quick ratio of 6.84 and a debt-to-equity ratio of 0.45.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported ($11.32) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $2.64 by ($13.96). United Therapeutics had a negative net margin of 9.36% and a negative return on equity of 5.78%. The company had revenue of $362.70 million for the quarter, compared to the consensus estimate of $335.72 million. During the same quarter in the prior year, the company earned $3.76 earnings per share. The company’s quarterly revenue was down 6.8% on a year-over-year basis. As a group, sell-side analysts predict that United Therapeutics will post -5.03 earnings per share for the current fiscal year.

In other United Therapeutics news, Director Christopher Patusky sold 3,370 shares of the company’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $110.75, for a total value of $373,227.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 8.20% of the stock is owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in UTHR. Oregon Public Employees Retirement Fund boosted its stake in shares of United Therapeutics by 10,537.5% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 3,551,229 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 3,517,845 shares during the period. Norges Bank purchased a new stake in shares of United Therapeutics during the fourth quarter valued at approximately $54,233,000. First Trust Advisors LP lifted its stake in United Therapeutics by 13.6% in the fourth quarter. First Trust Advisors LP now owns 1,196,804 shares of the biotechnology company’s stock worth $130,332,000 after acquiring an additional 143,235 shares during the period. Greylin Investment Mangement Inc. purchased a new stake in United Therapeutics in the fourth quarter worth $13,154,000. Finally, LSV Asset Management lifted its stake in United Therapeutics by 20.9% in the fourth quarter. LSV Asset Management now owns 616,549 shares of the biotechnology company’s stock worth $67,142,000 after acquiring an additional 106,460 shares during the period. 97.29% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

See Also: What is Net Asset Value (NAV)?

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.